SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the appointment of Wayne Gombotz, PhD as Chief Technology Officer. Dr. Gombotz has more than 30 years’ experience in the biotech and pharma industries and most recently served as the Chief Development Officer at Immune Design.
“We are pleased to welcome Wayne, a pioneer in the field and a key contributor to the biotechnology industry here in Seattle, to Alpine,” said Stanford Peng, MD PhD, President and Head of Research and Development for Alpine. “Wayne’s deep expertise developing therapies in oncology, infectious diseases, and autoimmune diseases will be a great addition to the Alpine team as we continue to advance our lead programs into and through the clinic.”
As Chief Development Officer at Immune Design, Dr. Gombotz was responsible for advancing several immuno-oncology products from bench to pivotal clinical trials. Prior to Immune Design, he held senior roles at Omeros Corporation, Corixa Corporation, and Amgen (formerly Immunex), where he played a major role in the development and launch of ENBREL®, one of the top-selling drugs for psoriasis and multiple arthritis conditions.
Dr. Gombotz currently serves as an Advisory Board Member for the University of Washington's Department of Bioengineering and was a recent recipient of the University of Washington College of Engineering’s 2019 Diamond Award for Distinguished Achievement in Industry.
Dr. Gombotz holds a PhD and MS in Bioengineering from the University of Washington and a BA in biology from Colby College.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of functional immune therapeutics. Alpine is employing directed evolution to create potentially powerful multifunctional immunotherapies to improve patients’ lives. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28 antagonist, engineered to reduce pathogenic immune responses. ALPN-101 is currently enrolling a Phase I healthy volunteer trial. The second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 costimulator intended to combine checkpoint inhibition with T cell costimulation - an approach currently absent from approved checkpoint therapies. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.